Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Histone deacetylase Stories

2012-01-10 23:35:12

University of Leicester scientists announce a major advance in understanding the regulation of an important cancer target in Nature paper Scientists at the University of Leicester have opened up a whole new approach to the therapeutic intervention for a family of anti-cancer drug targets, thanks to a completely new and unexpected finding. Professor Schwabe and his colleagues, Drs Watson, Fairall and Santos, have published their research this week in leading science magazine Nature...

2012-01-09 08:00:00

EAST SETAUKET, N.Y., Jan. 9, 2012 /PRNewswire/ -- Lixte Biotechnology Holdings (OTC: LIXT.PK) announces that the United States Patent and Trademark Office awarded a patent for the use of lead compounds from each of two different types of drugs, protein phosphatase inhibitors and histone deacetylase inhibitors, for the potential prevention and treatment of neurodegenerative diseases. Dr. John S. Kovach, founder and president of Lixte, said, "We have developed a series of novel...

2011-12-28 08:12:12

The findings could point the way to new therapies Scientists at The Scripps Research Institute have discovered that DNA stays too tightly wound in certain brain cells of schizophrenic subjects. The findings suggest that drugs already in development for other diseases might eventually offer hope as a treatment for schizophrenia and related conditions in the elderly. The research, now available online in the new Nature journal, Translational Psychiatry, shows the deficit is especially...

2011-12-19 08:00:00

EAST SETAUKET, N.Y., Dec. 19, 2011 /PRNewswire/ -- An article in the early edition (December 12, 2011) of the Proceedings of the National Academy of Sciences USA, reported that Lixte's investigational drug, LB-205, was shown to have therapeutic potential in a laboratory model of Gaucher disease (http://www.pnas.org/content/early/2011/12/08/1119181109.full.pdf+html). John Kovach, MD, founder and president of Lixte said, "This is a novel use of the class of drugs known as histone...

2011-12-13 13:05:25

National Phase III clinical trial will test histone deacetylase inhibitor with frontline therapy Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center reported at the 53rd Annual Meeting of the American Society of Hematology. Results of the Phase II clinical trial of 75 patients set the stage for a national Phase III...

2011-12-11 20:00:00

WALTHAM, Mass., Dec. 11, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma (HL). This data is being presented today, December 11, from 6:00 to 8:00 PM PT at the American Society of Hematology Annual Meeting and Exposition...

Substance In Cancer Medicine May Help Prevent Heart Attacks
2011-11-24 06:00:51

Researchers at the Sahlgrenska Academy at the University of Gothenburg, Sweden have been using a substance found in cancer and epilepsy drugs to help stimulate the body´s natural defense mechanism against blood clots. The body contains a system that helps break down blood clots before they can damage the heart, called the fibrinolytic system. This system “sprays” an enzyme on the clot before it can stop blood flow to the heart, causing a heart attack. This system can be...

2011-11-22 07:00:00

SINGAPORE, Nov. 22, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that data from Phase 2 studies for its JAK2 inhibitor pacritinib (SB1518) and histone deacetylase inhibitor pracinostat (SB939) demonstrate promising activity in patients with myelofibrosis (MF). Results will be presented at the 53rd ASH Annual Meeting and Exposition in San Diego, Calif. "Pacritinib has been well tolerated and has shown activity in alleviating MF-associated splenomegaly and...

2011-11-14 11:36:38

Clinical benefit from use of a novel histone deacetylase inhibitor drug may be determined by examining blood cells days after a patient receives treatment. The drug, entinostat, is the first histone deacetylase inhibitor successfully tested in a randomized, placebo-controlled study in metastatic breast cancer – and is the first to show that clinical outcome can be predicted shortly after administration. The findings, reported at the AACR-NCI-EORTC International Conference: Molecular...

2011-11-14 11:35:29

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer. They also found that introducing a novel histone deacetylase inhibitor in hormone therapy treatment can overcome resistance to hormonal therapy. "We always thought that resistance was primarily an inborn or genetic effect," said Pamela N. Munster, M.D., director of the Early-Phase Clinical...